# An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids

> **NCT00799266** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 34 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Zoledronic acid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00799266
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-04
- **Primary completion:** 2018-03-05
- **Final completion:** 2018-03-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2020-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00799266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00799266, "An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00799266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*